Stiefel Janis, Zimmer Jan, Schloßhauer Jeffrey L, Vosen Agnes, Kilz Sarah, Balakin Sascha
Fraunhofer Institute for Microengineering and Microsystems IMM, Carl-Zeiss-Straße 18-20, 55129 Mainz, Germany.
Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses IZI-BB, Am Mühlenberg 13, 14476 Potsdam, Germany.
Vaccines (Basel). 2023 Jul 27;11(8):1287. doi: 10.3390/vaccines11081287.
In light of the recent pandemic, several COVID-19 vaccines were developed, tested and approved in a very short time, a process that otherwise takes many years. Above all, these efforts have also unmistakably revealed the capacity limits and potential for improvement in vaccine production. This review aims to emphasize recent approaches for the targeted rapid adaptation and production of vaccines from an interdisciplinary, multifaceted perspective. Using research from the literature, stakeholder analysis and a value proposition canvas, we reviewed technological innovations on the pharmacological level, formulation, validation and resilient vaccine production to supply bottlenecks and logistic networks. We identified four main drivers to accelerate the vaccine product life cycle: computerized candidate screening, modular production, digitized quality management and a resilient business model with corresponding transparent supply chains. In summary, the results presented here can serve as a guide and implementation tool for flexible, scalable vaccine production to swiftly respond to pandemic situations in the future.
鉴于最近的疫情大流行，几种新冠疫苗在极短的时间内就得以研发、测试和批准，而这个过程通常需要很多年。最重要的是，这些努力也明确揭示了疫苗生产中的能力限制和改进潜力。本综述旨在从跨学科、多方面的角度强调近期有针对性地快速调整和生产疫苗的方法。我们利用文献研究、利益相关者分析和价值主张画布，回顾了在药理学层面、配方、验证以及应对供应瓶颈和物流网络的弹性疫苗生产方面的技术创新。我们确定了加速疫苗产品生命周期的四个主要驱动因素：计算机化候选筛选、模块化生产、数字化质量管理以及具有相应透明供应链的弹性商业模式。总之，本文给出的结果可作为灵活、可扩展疫苗生产的指南和实施工具，以便未来能迅速应对疫情形势。
